VYGR
Income statement / Annual
Last year (2025), Voyager Therapeutics Inc's total revenue was $40.37 M,
a decrease of 49.53% from the previous year.
In 2025, Voyager Therapeutics Inc's net income was -$119.72 M.
See Voyager Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$40.37 M |
$80.00 M |
$250.01 M |
$40.91 M |
$37.42 M |
$171.13 M |
$104.39 M |
$7.62 M |
$10.14 M |
$14.22 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$92.17 M
|
$55.76 M
|
$73.79 M
|
$108.75 M
|
$119.74 M
|
$64.91 M
|
$62.26 M
|
$42.25 M
|
| Gross Profit |
$40.37 M
|
$80.00 M
|
$157.84 M
|
-$14.86 M
|
-$36.37 M
|
$62.38 M
|
-$15.34 M
|
-$57.29 M
|
-$52.13 M
|
-$28.03 M
|
| Gross Profit Ratio |
1
|
1
|
0.63
|
-0.36
|
-0.97
|
0.36
|
-0.15
|
-7.52
|
-5.14
|
-1.97
|
| Research and Development Expenses |
$134.67 M
|
$127.37 M
|
$92.17 M
|
$60.76 M
|
$73.79 M
|
$108.75 M
|
$119.74 M
|
$64.91 M
|
$62.26 M
|
$42.25 M
|
| General & Administrative Expenses |
$37.54 M
|
$35.92 M
|
$35.82 M
|
$30.98 M
|
$37.25 M
|
$34.99 M
|
$36.34 M
|
$33.81 M
|
$19.74 M
|
$13.27 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$37.54 M
|
$35.92 M
|
$35.82 M
|
$30.98 M
|
$37.25 M
|
$34.99 M
|
$36.34 M
|
$33.81 M
|
$19.74 M
|
$13.27 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$92.17 M
|
-$55.76 M
|
-$73.79 M
|
-$108.75 M
|
-$119.74 M
|
$2.63 M
|
$1.17 M
|
$1.16 M
|
| Operating Expenses |
$172.22 M
|
$163.29 M
|
$35.82 M
|
$35.98 M
|
$37.25 M
|
$34.99 M
|
$36.34 M
|
$98.71 M
|
$82.00 M
|
$55.52 M
|
| Cost And Expenses |
$172.22 M
|
$163.29 M
|
$127.99 M
|
$91.74 M
|
$111.03 M
|
$143.74 M
|
$156.07 M
|
$98.71 M
|
$82.00 M
|
$55.52 M
|
| Interest Income |
$10.62 M
|
$18.33 M
|
$11.72 M
|
$1.79 M
|
$0.00
|
$1.66 M
|
$6.46 M
|
$3.31 M
|
$1.23 M
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$976.00 K
|
| Depreciation & Amortization |
$4.06 M
|
$4.73 M
|
$4.44 M
|
$6.19 M
|
$5.17 M
|
$3.82 M
|
$2.77 M
|
$2.12 M
|
$1.60 M
|
$612.00 K
|
| EBITDA |
-$127.78 M |
-$78.56 M |
$126.46 M |
-$39.65 M |
-$68.45 M |
$31.20 M |
-$48.91 M |
-$88.98 M |
-$70.27 M |
-$40.69 M |
| EBITDA Ratio |
-3.17
|
-0.98
|
0.51
|
-0.97
|
-1.83
|
0.18
|
-0.47
|
-11.68
|
-6.93
|
-2.86
|
| Operating Income Ratio |
-3.27
|
-1.04
|
0.49
|
-1.24
|
-1.97
|
0.16
|
-0.5
|
-11.96
|
-7.09
|
-2.9
|
| Total Other Income/Expenses Net |
$12.27 M
|
$18.95 M
|
$11.72 M
|
$4.45 M
|
$2.42 M
|
$9.36 M
|
$8.08 M
|
$2.63 M
|
$1.17 M
|
$1.16 M
|
| Income Before Tax |
-$119.58 M
|
-$64.34 M
|
$133.74 M
|
-$46.39 M
|
-$71.20 M
|
$36.74 M
|
-$43.60 M
|
-$88.47 M
|
-$70.70 M
|
-$40.14 M
|
| Income Before Tax Ratio |
-2.96
|
-0.8
|
0.53
|
-1.13
|
-1.9
|
0.21
|
-0.42
|
-11.61
|
-6.98
|
-2.82
|
| Income Tax Expense |
$144.00 K
|
$665.00 K
|
$1.41 M
|
$16.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$180.00 K
|
$0.00
|
$52.00 K
|
| Net Income |
-$119.72 M
|
-$65.00 M
|
$132.33 M
|
-$46.41 M
|
-$71.20 M
|
$36.74 M
|
-$43.60 M
|
-$88.29 M
|
-$70.70 M
|
-$40.19 M
|
| Net Income Ratio |
-2.97
|
-0.81
|
0.53
|
-1.13
|
-1.9
|
0.21
|
-0.42
|
-11.59
|
-6.98
|
-2.83
|
| EPS |
-2.04 |
-1.13 |
3.08 |
-1.21 |
-1.75 |
0.99 |
-1.14 |
-2.75 |
-2.64 |
-1.59 |
| EPS Diluted |
-2.04 |
-1.13 |
2.97 |
-1.21 |
-1.75 |
0.98 |
-1.14 |
-2.75 |
-2.64 |
-1.59 |
| Weighted Average Shares Out |
$58.69 M
|
$57.67 M
|
$43.02 M
|
$38.36 M
|
$37.67 M
|
$37.13 M
|
$35.90 M
|
$32.07 M
|
$26.80 M
|
$25.30 M
|
| Weighted Average Shares Out Diluted |
$58.69 M
|
$57.67 M
|
$44.57 M
|
$38.36 M
|
$37.67 M
|
$37.35 M
|
$35.90 M
|
$32.07 M
|
$26.80 M
|
$25.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
